Psychiatry
Treatment Resistant Depression
60
Pipeline Programs↗
27
Active Trials↗
36
Companies Involved↗
Treatment Resistant Depression is a moderately active landscape with 60 programs across 36 companies. The most active players are Retrophin, Teva, Pfizer. 13 therapies are approved with 7 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical19
Phase 15
Phase 216
Phase 37
Analysis
Trial Status
127
clinical trials
Completed69 · 54%
Recruiting19 · 15%
Terminated12 · 9%
Unknown status11 · 9%
Withdrawn8 · 6%
Not yet recruiting5 · 4%
Other3 · 2%
Clinical Trials
Trial Activity
127 trials
Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression
Recruiting·—·Phase 2·NCT07183748·20 enrolled
Ketamine Alcohol (in Treatment-Resistant Depression)
Recruiting·—·Phase 2·NCT02122562·60 enrolled
Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression
Recruiting·—·N/A·NCT07146503·100 enrolled
Page 1 of 9
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)